Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Signs On As Shire’s Vyvanse Promotion Partner

This article was originally published in The Pink Sheet Daily

Executive Summary

Addition of GSK’s 600 sales reps will more than double the reach of Shire’s current promotional effort for the ADHD medication.

You may also be interested in...



Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market

In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications

Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market

In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications

ADHD Market Snapshot: Changes Blow In With Adderall XR Generics

The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel